SuperworthRoyalty Pharma plc RPRX
Medical - Pharmaceuticals, Healthcare
$56.52
−0.42%
- Market cap
- $32.5B
- PE
- 30.2×
- 10y median 27.6×
- Forward PE
- Price to sales
- 12.9×
- EV/EBIT
- 27.6×
- Revenue, 12 months
- $2.5B
- +10% on a year ago
- Net margin
- 32.0%
- Free cash flow yield
- 9.1%
Royalty Pharma trades at 30.2× trailing earnings, near its ten-year median. Revenue was $2.5B over the last twelve months, up 10% on a year earlier with a 32% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $596.1M | $568M | $537.3M | $564.7M | $593.6M−0% | $568.2M+0% | $578.7M+8% | $609.3M+8% | $622M+5% | $630.6M+11% | $674.1M+17% | |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.2M | $268.2M |
| Gross profit | — | — | — | — | — | — | — | — | — | $629.4M | $405.9M |
| R&D | $500K | $500K | $500K | $500K | $500K+0% | $50.5M+10000% | $300.5M+60000% | $50.5M+10000% | $50.5M+10000% | $39.8M−21% | $97.9M−67% |
| SG&A | $59.2M | $57.7M | $54.7M | $56.7M | $67.6M+14% | $110.7M+92% | $179.8M+229% | $118.7M+109% | $164.3M+143% | $159M+44% | $161.9M−10% |
| $612.9M | −$73.8M | $269.6M | $735.1M | $361.5M−41% | $534.2M | $209.8M−22% | $427.2M−42% | $388.4M+7% | $563M+5% | $133.1M−37% | |
| Interest expense | $47.3M | $44.2M | $49M | $66.5M | $65.8M+39% | $65.3M+48% | $68.7M+40% | $79.6M+20% | $94.2M+43% | $93.7M+44% | $93.6M+36% |
| Pre-tax income | $717.6M | −$4.3M | $194.4M | $806.4M | $334.4M−53% | $434.4M | $92.6M−52% | $441.2M−45% | $355.9M+6% | $468.3M+8% | $81.5M−12% |
| Net income | $494.3M | $4.8M | $102M | $544M | $208.2M−58% | $239.3M+4909% | $32.2M−69% | $285.2M−48% | $214.2M+3% | $294.7M+23% | $17.9M−44% |
| $1.10 | $0.01 | $0.23 | $1.21 | $0.47−57% | $0.55+5400% | $0.07−70% | $0.67−45% | $0.50+6% | $0.67+22% | $0.04−43% | |
| 602M | 597.5M | 596.9M | 592.7M | 589M−2% | 578.1M−3% | 562.3M−6% | 559.6M−6% | 559.6M−5% | 556.8M−4% | 556.9M−1% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Healthcare within ten times Royalty Pharma's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RPRXRoyalty Pharma plc | $32.6B | 30.2× | 27.6× | 12.9× | +10% | 32.0% | |
| RMDResMed Inc. | $32.6B | 21.7× | 37.3× | 5.8× | +10% | 26.9% | |
| BIIBBiogen Inc. | $32.8B | 39.3× | 16.1× | 3.3× | +0% | 8.3% | |
| DXCMDexCom, Inc. | $31.8B | 33.3× | 142× | 6.4× | +16% | 20.1% | |
| MTDMettler-Toledo International Inc. | $30.7B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| ALNYAlnylam Pharmaceuticals, Inc. | $30B | 37.8× | 121× | 6.3× | +95% | 16.1% | |
| ZTSZoetis Inc. | $29.6B | 11.8× | 37.8× | 3.1× | +1% | 27.7% | |
| GEHCGE HealthCare Technologies Inc. | $29.2B | 18.7× | 19.9× | 1.4× | +7% | 9.3% | |
| IDXXIDEXX Laboratories, Inc. | $39.9B | 35.6× | 54.8× | 8.8× | +13% | 25.0% | |
| ILMNIllumina, Inc. | $40.4B | 49.9× | 50.6× | 9.0× | +5% | 18.4% | |
| WSTWest Pharmaceutical Services, Inc. | $25.8B | 46.9× | 45.8× | 7.8× | +12% | 17.0% | |
| Peer median | $31.3B | 35.1× | 41.8× | 6.3× | +8% | 19.2% |
About
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .